Compare Sun Pharma with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs PANACEA BIOTECH - Comparison Results

SUN PHARMA     Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA PANACEA BIOTECH SUN PHARMA/
PANACEA BIOTECH
 
P/E (TTM) x 18.4 4.5 407.5% View Chart
P/BV x 2.0 1.8 111.5% View Chart
Dividend Yield % 0.8 0.0 -  

Financials

 SUN PHARMA   PANACEA BIOTECH
EQUITY SHARE DATA
    SUN PHARMA
Mar-19
PANACEA BIOTECH
Mar-19
SUN PHARMA/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs679354 192.0%   
Low Rs375138 271.6%   
Sales per share (Unadj.) Rs121.174.6 162.5%  
Earnings per share (Unadj.) Rs13.46.7 200.3%  
Cash flow per share (Unadj.) Rs20.715.5 133.5%  
Dividends per share (Unadj.) Rs2.750-  
Dividend yield (eoy) %0.50-  
Book value per share (Unadj.) Rs172.657.2 301.7%  
Shares outstanding (eoy) m2,399.2661.25 3,917.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.43.3 131.9%   
Avg P/E ratio x39.436.8 107.0%  
P/CF ratio (eoy) x25.515.9 160.6%  
Price / Book Value ratio x3.14.3 71.1%  
Dividend payout %20.60-   
Avg Mkt Cap Rs m1,264,65015,061 8,396.6%   
No. of employees `00017.52.3 756.3%   
Total wages/salary Rs m59,6711,471 4,057.0%   
Avg. sales/employee Rs Th16,608.11,973.6 841.5%   
Avg. wages/employee Rs Th3,409.6635.6 536.4%   
Avg. net profit/employee Rs Th1,833.8176.8 1,037.3%   
INCOME DATA
Net Sales Rs m290,6594,567 6,364.3%  
Other income Rs m10,25545 22,890.4%   
Total revenues Rs m300,9144,612 6,524.9%   
Gross profit Rs m63,0762,030 3,107.6%  
Depreciation Rs m17,533540 3,246.8%   
Interest Rs m5,5531,048 529.7%   
Profit before tax Rs m50,246486 10,334.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-12,1440-   
Tax Rs m6,00977 7,793.5%   
Profit after tax Rs m32,093409 7,844.8%  
Gross profit margin %21.744.4 48.8%  
Effective tax rate %12.015.9 75.4%   
Net profit margin %11.09.0 123.3%  
BALANCE SHEET DATA
Current assets Rs m310,6922,415 12,867.8%   
Current liabilities Rs m173,3969,077 1,910.2%   
Net working cap to sales %47.2-145.9 -32.4%  
Current ratio x1.80.3 673.6%  
Inventory Days Days9965 152.2%  
Debtors Days Days11271 157.3%  
Net fixed assets Rs m232,4778,333 2,789.7%   
Share capital Rs m2,39961 3,914.0%   
"Free" reserves Rs m411,6913,443 11,958.3%   
Net worth Rs m414,0913,504 11,817.7%   
Long term debt Rs m15,226461 3,301.4%   
Total assets Rs m646,93813,755 4,703.2%  
Interest coverage x10.01.5 686.5%   
Debt to equity ratio x00.1 27.9%  
Sales to assets ratio x0.40.3 135.3%   
Return on assets %5.810.6 54.9%  
Return on equity %7.811.7 66.4%  
Return on capital %10.238.7 26.3%  
Exports to sales %020.9 0.0%   
Imports to sales %08.1 0.0%   
Exports (fob) Rs mNA954 0.0%   
Imports (cif) Rs mNA372 0.0%   
Fx inflow Rs m66,0251,203 5,488.3%   
Fx outflow Rs m38,610467 8,273.7%   
Net fx Rs m27,415736 3,723.0%   
CASH FLOW
From Operations Rs m21,9651,049 2,094.3%  
From Investments Rs m-6,813-54 12,733.6%  
From Financial Activity Rs m-27,305-1,011 2,699.7%  
Net Cashflow Rs m-8,442-20 42,850.3%  

Share Holding

Indian Promoters % 63.7 74.5 85.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 0.6 855.0%  
FIIs % 23.0 1.3 1,769.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 23.6 35.2%  
Shareholders   133,026 10,259 1,296.7%  
Pledged promoter(s) holding % 0.5 35.1 1.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   CIPLA  PFIZER  NATCO PHARMA  SHASUN PHARMA  PIRAMAL ENTERPRISES  

Compare SUN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Volatile Day for Indian Indices: Sensex Ends 131 Points Lower Post Rebound; Telecom and Auto Stocks Bleed(Closing)

It was a volatile day for India share markets today. The benchmark indices opened higher but turned volatile.

Related Views on News

SUN PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 29.8% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, SUN PHARMA has posted a net profit of Rs 10 bn (down 29.8% YoY). Sales on the other hand came in at Rs 82 bn (up 5.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

More Views on News

Most Popular

This Crorepati Stock Could Be the Best Vaccine for Your Portfolio Against Coronavirus(Profit Hunter)

Mar 17, 2020

If there is one stock I had to recommend you amid Coronavirus outbreak, this would be it.

If I Were to Recommend One Stock Amid Coronavirus Outbreak, This Would be It.(Profit Hunter)

Mar 19, 2020

Coronavirus outbreak has made no impact on the long term prospects of my favourite smallcap. What it has indeed done is brought the company below my buy price, making it even more attractive investment at current price.

Why India Will Be the Biggest Winner in a Post-Coronavirus World(The 5 Minute Wrapup)

Mar 19, 2020

The way businesses operate will change in a major way post the coronavirus impact. Here's why India stands to benefit from this change...

A Big Trading Opportunity is Coming Your Way Soon(Fast Profits Daily)

Mar 25, 2020

I see a big opportunity to make fast profits on the horizon.

The Biggest Trading Opportunity of 2020 is Here...

Mar 26, 2020

India's #1 trader, Vijay Bhambwani, talks about a hugely profitable trading opportunity which you must know about today!

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Mar 27, 2020 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA 8-QTR ANALYSIS

COMPARE SUN PHARMA WITH

MARKET STATS